Development of High-Performance Products Based on Biomatrix Research
First written in FY2016. 17 of 27 entries say "Restated". Latest entry: FY2026.
59 other companies' latest entry also says "Advanced".
- FY2026AdvancedAnnual report
「We promoted the practical application and advancement of our proprietary high-efficiency recombinant protein production system, spERt® technology. In developing three-dimensional cell culture substrates, we continued product development aimed at adoption by global pharmaceutical companies, using fibrous collagen and major components of the basement membrane in response to growing demand for alternatives to animal testing and NAMs (New Approach Methodologies). Research and development expenses for the fiscal year were ¥766 million.」
The practical application and advancement of spERt® and the development of difficult-to-express proteins and three-dimensional cell culture substrates progressed, and research and development expenses were ¥766 million. - FY2026-H1RestatedAnnual report
「Total research and development expenses for the six-month period of the current fiscal year were ¥345 million. There were no material changes in the status of the Group's research and development activities during the six-month period of the current fiscal year.」
Research and development expenses of ¥345 million were recorded, and it was stated that there were no material changes in the status of research and development activities. - FY2025AdvancedAnnual report
「During the fiscal year, research and development activities ranged broadly from basic science to applied technology development aimed at commercialization. In the field of three-dimensional cell culture, we have developed and marketed the MatriMix series of cell culture substrates in response to the growing importance of alternatives to animal testing. Research and development expenses for the fiscal year were ¥595 million.」
Research and development from basic research through commercialization continued, and applied fields were expanded through activities including the development and marketing of the MatriMix series. Research and development expenses were ¥595 million. - FY2025-H1RestatedAnnual report
「Total research and development expenses for the six-month period of the current fiscal year were ¥331 million. There were no material changes in the status of the Group's research and development activities during the six-month period of the current fiscal year.」
Research and development expenses were ¥331 million, and it was stated that there were no material changes in the status of research and development activities. - FY2024-Q3RestatedAnnual report
「Total research and development expenses for the first nine months of the current fiscal year were ¥426 million. There were no material changes in the status of the Group's research and development activities during the first nine months of the current fiscal year.」
Research and development expenses were ¥426 million, and it was stated that there were no material changes in the status of research and development activities. - FY2024-Q2RestatedAnnual report
「Total research and development expenses for the first six months of the current fiscal year were ¥281 million. There were no material changes in the status of the Group's research and development activities during the first six months of the current fiscal year.」
Research and development expenses were ¥281 million, and it was stated that there were no material changes in the status of research and development activities. - FY2024-Q1RestatedAnnual report
「Total research and development expenses for the first quarter of the current fiscal year were ¥142 million. There were no material changes in the status of the Group's research and development activities during the first quarter of the current fiscal year.」
Research and development expenses were ¥142 million, and it was stated that there were no material changes in the status of research and development activities. - FY2023AdvancedAnnual report
「During the fiscal year, research and development activities covered a broad range, from basic science to applied technology and product development aimed at commercialization. Areas included the development of 3D cell culture-related products; dermatological research for cosmetics development; nutritional and physiological research on oral collagen intake; the development of novel recombinant proteins for applications in oncology and immunology in collaboration with universities, research institutions and companies; and broad basic research on collagen and other subjects in collaboration with academic institutions in Japan and overseas.」
Research and development expenses were ¥818 million, reflecting expanded activities from basic research through commercialization in areas including three-dimensional cell culture, recombinant proteins, medical collagen, cosmetics and oral collagen intake. - FY2023-Q3RestatedAnnual report
「Total research and development expenses for the third quarter of the current consolidated cumulative period amounted to ¥585 million. There were no material changes in the status of the Group's research and development activities during the third quarter of the current consolidated cumulative period.」
The company reported research and development expenses of ¥585 million and no material changes in the status of its research and development activities. - FY2023-Q1RestatedAnnual report
「Total research and development expenses for the first quarter of the current consolidated cumulative period amounted to ¥195 million. There were no material changes in the status of the Group's research and development activities during the first quarter of the current consolidated cumulative period.」
The company reported research and development expenses of ¥195 million and no material changes in the status of its research and development activities. - FY2022AdvancedAnnual report
「During the fiscal year, research and development activities focused on the development of new products and technologies, research into the efficacy of existing products and the creation of higher value added. A broad range of activities was conducted, from basic science to applied development aimed at commercialization, including the development of 3D cell culture-related products; recombinant proteins for applications in oncology and immunology; dermatology for cosmetics development; nutritional physiology relating to oral collagen intake; and tissue engineering involving high-concentration collagen substrates.」
The scope and applications of research and development expanded to 3D cell culture, recombinant proteins, medical-use collagen, cosmetics and oral collagen intake, among other areas. Research and development expenses amounted to ¥518 million. - FY2022-Q3RestatedAnnual report
「Total research and development expenses for the third quarter of the current consolidated cumulative period amounted to ¥322 million. There were no material changes in the status of the Group's research and development activities during the third quarter of the current consolidated cumulative period.」
The company reported research and development expenses of ¥322 million and no material changes in the status of its research and development activities. - FY2022-Q1RestatedAnnual report
「Total research and development expenses for the first quarter of the current consolidated cumulative period amounted to ¥112 million. There were no material changes in the status of the Group's research and development activities during the first quarter of the current consolidated cumulative period.」
The company reported research and development expenses of ¥112 million and no material changes in the status of its research and development activities. - FY2021AdvancedAnnual report
「During the fiscal year, research and development activities focused on extracellular matrix components represented by collagen and laminin, for the development of new products and technologies, research into the efficacy of existing products, and the creation of higher value added. Research and development was also conducted in regenerative medicine and tissue engineering, the development of cell culture-related products, dermatology for cosmetics development, and nutritional science relating to oral collagen intake.」
Research and development continued in extracellular matrices, regenerative medicine, cell culture, cosmetics and collagen nutrition, and research and development expenses amounted to ¥597 million. - FY2020AdvancedAnnual report
「During the fiscal year, research and development activities focused on extracellular matrix components represented by collagen and laminin, for the development of new products and technologies, research into the efficacy of existing products, and the creation of higher value added. Research and development was also conducted in regenerative medicine and tissue engineering, the development of cell culture-related products, dermatology for cosmetics development, and nutritional science relating to oral collagen intake. Research and development expenses for the fiscal year amounted to ¥511 million.」
The scope of research was expanded to regenerative medicine and tissue engineering, cell culture, cosmetics and collagen nutrition, among other areas, and research and development expenses amounted to ¥511 million. The development of the iMatrix series and recombinant antibody protein technology was also reported. - FY2020-Q1RestatedAnnual report
「Total research and development expenses for the first quarter of the current consolidated cumulative period amounted to ¥116 million. There were no material changes in the status of the Group's research and development activities during the first quarter of the current consolidated cumulative period.」
The company reported research and development expenses of ¥116 million and no material changes in the status of its research and development activities. - FY2019AdvancedAnnual report
「During the fiscal year, research and development activities focused on extracellular matrix components represented by collagen and laminin, for the development of new products and technologies, research into the efficacy of existing products, and the creation of higher value added. Research and development was also conducted in regenerative medicine and tissue engineering, the development of cell culture-related products, dermatology for cosmetics development, and nutritional science relating to oral collagen intake. Research and development expenses for the fiscal year amounted to ¥491 million.」
The scope of research was expanded to regenerative medicine and tissue engineering, cell culture, cosmetics and collagen nutrition, among other areas, and research and development expenses amounted to ¥491 million. - FY2019-Q3RestatedAnnual report
「Total research and development expenses for the third quarter of the current consolidated cumulative period amounted to ¥363 million. There were no material changes in the status of the Group's research and development activities during the third quarter of the current consolidated cumulative period.」
The company reported research and development expenses of ¥363 million and no material changes in the status of its research and development activities. - FY2019-Q2RestatedAnnual report
「Total research and development expenses for the second quarter of the current consolidated cumulative period amounted to ¥260 million. There were no material changes in the status of the Group's research and development activities during the second quarter of the current consolidated cumulative period.」
The company reported research and development expenses of ¥260 million and no material changes in the status of its research and development activities. - FY2019-Q1RestatedAnnual report
「Total research and development expenses for the first quarter of the current consolidated cumulative period amounted to ¥120 million. There were no material changes in the status of the Group's research and development activities during the first quarter of the current consolidated cumulative period.」
The company reported research and development expenses of ¥120 million and no material changes in the status of its research and development activities. - FY2018AdvancedAnnual report
「During the fiscal year, research and development activities focused on extracellular matrices represented by collagen, gelatin and laminin, for the development of new products and technologies, improvement and enhancement of existing products, and the creation of higher value added. Basic research was conducted in biochemistry, molecular biology, cell biology, nutrition and physiology, among other fields, together with applied development for regenerative medicine. Research and development expenses for the fiscal year amounted to ¥462 million.」
The scope of research and development was expanded to extracellular matrices, regenerative medicine, medical and cosmetic materials, health foods and other areas, and research and development expenses amounted to ¥462 million. - FY2018-Q2RestatedAnnual report
「Going forward, under our consistent philosophy of maintaining a commitment to quality and moving forward together with our stakeholders, we will further deepen our biomatrix research, one of our strengths, and promote the development of a wide range of high-function products. Through these efforts, we aim to expand our business fields, establish a high-profitability business structure and maximize corporate value.」
The policy of maintaining a commitment to quality, deepening biomatrix research, developing high-function products, expanding the business fields and establishing a high-profitability business structure was reiterated. - FY2017AdvancedAnnual report
「We supply the market with the new cell culture substrate iMatrix511, developed through joint research with Osaka University and Kyoto University, which enables the efficient culture of iPS and ES cells, as well as iMatrix511MG, which can also be used for clinical applications. Research and development expenses for the fiscal year amounted to ¥103 million.」
The company reported that it supplies iMatrix511MG for clinical use in addition to iMatrix511, and is advancing the development of medical-use and cosmetic-use collagen, MediGelatin, collagen peptides and other products. - FY2017-Q3RestatedAnnual report
「Going forward, under our consistent philosophy of maintaining a commitment to quality and moving forward together with our stakeholders, we will further deepen our biomatrix research, one of our strengths, and promote the development of a wide range of high-function products. Through these efforts, we aim to expand our business fields, establish a high-profitability business structure and maximize corporate value.」
The policy of deepening biomatrix research, developing high-function products, expanding the business fields and establishing a high-profitability business structure was reiterated. - FY2017-Q2RestatedAnnual report
「Going forward, under our consistent philosophy of maintaining a commitment to quality and moving forward together with our stakeholders, we will further deepen our biomatrix research, one of our strengths, and promote the development of a wide range of high-function products. Through these efforts, we aim to expand our business fields, establish a high-profitability business structure and maximize corporate value.」
The policy of deepening biomatrix research, developing high-function products, expanding the business fields and establishing a high-profitability business structure was reiterated. - FY2017-Q1RestatedAnnual report
「Going forward, under our consistent philosophy of maintaining a commitment to quality and moving forward together with our stakeholders, we will further deepen our biomatrix research, one of our strengths, and promote the development of a wide range of high-function products. Through these efforts, we aim to expand our business fields, establish a high-profitability business structure and maximize corporate value.」
The policy of pursuing biomatrix research, developing high-function products, expanding the business fields and establishing a high-profitability business structure was reiterated. - FY2016First statedAnnual report
「Going forward, under our consistent philosophy of maintaining a commitment to quality and moving forward together with our stakeholders, we will further deepen our biomatrix research, one of our strengths, and promote the development of a wide range of high-function products. Through these efforts, we aim to expand our business fields, establish a high-profitability business structure and maximize corporate value.」
We are developing high-value-added products for medical, cosmetic and health food applications based on extracellular matrices such as collagen, gelatin and laminin.